JOHANNESBURG, May 29 – Africa’s largest pharmaceutical manufacturer, Aspen Pharmacare Holdings Limited has completed the sale of its Asia-Pacific business, concluding one of the largest strategic transactions in the company’s recent history and generating approximately R27 billion (about $1.7 Billion) in net proceeds.
The divested business included operations across Australia, New Zealand and several Asia-Pacific markets, excluding China.
The transaction was completed at a total consideration of AUD 2.37 billion, with the final purchase price remaining unchanged from the amount originally announced.
According to Aspen, the deal materially strengthens the company’s balance sheet and provides greater financial flexibility as it evaluates future growth opportunities and capital allocation strategies.
Chief Executive Officer Stephen Saad described the transaction as a significant milestone in Aspen’s long-term strategy to unlock shareholder value and demonstrate the strength of the businesses developed within the group.
Saad noted that the Asia-Pacific division began as a relatively small operation before evolving into a major contributor to the company’s earnings, cash generation and overall market value.
He said the successful sale reflects Aspen’s ability to build, scale and enhance pharmaceutical businesses across international markets before realizing value through strategic transactions.
The company confirmed that transaction-related expenses amounted to less than 5% of the total deal value, in line with previous guidance provided to shareholders.
Net proceeds from the sale have primarily been directed toward reducing group debt, a move that significantly improves Aspen’s financial position and lowers leverage levels.
Management indicated that the strengthened balance sheet creates additional flexibility to pursue future investments, acquisitions and other strategic opportunities.
The company also signaled that enhanced financial capacity could support future shareholder-return initiatives, including potential share repurchase programs.
Aspen’s board stated that it believes the current market valuation does not fully reflect the underlying value of the group’s remaining businesses, particularly given its improved financial profile and future earnings potential.
The completion of the transaction marks the end of Aspen’s ownership of the Asia-Pacific operation and the beginning of a new phase for the business under its new owners.
The company expressed appreciation to employees, management teams and stakeholders who contributed to the growth of the Asia-Pacific division over the years and wished the business continued success in its next chapter.
The divestment represents one of the most significant value-unlocking transactions undertaken by Aspen and positions the pharmaceutical group with greater financial strength as it focuses on its next phase of growth.
